M&A Deal Summary |
|
|---|---|
| Date | 2011-03-28 |
| Target | ChemGenex Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Cephalon |
| Sellers(s) | Alta Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 231M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1987 |
| Sector | Life Science |
| Employees | 3,726 |
Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 7 |
| Sector: Life Science M&A | 7 of 7 |
| Type: Add-on Acquisition M&A Deals | 6 of 6 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 4 of 4 |
| Year: 2011 M&A | 2 of 2 |
| Size (of disclosed) | 3 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-03-22 |
Gemin X Biotechnologies
Montreal, Quebec, Canada Gemin X Biotechnologies Inc. is a biopharmaceutical company that engages in the discovery and development of small molecule cancer therapeutics based on the regulation of apoptosis. The company develops small molecules that target pathways for cancer, including regulators in the genesis and progression of cancer. |
Buy | $225M |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 2.6B USD |
| Size | Large |
| Type | Sector Focused |
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 50 of 85 |
| Sector: Life Science M&A | 35 of 65 |
| Type: Add-on Acquisition M&A Deals | 35 of 45 |
| State: California M&A | 22 of 41 |
| Country: United States M&A | 43 of 75 |
| Year: 2011 M&A | 4 of 7 |
| Size (of disclosed) | 16 of 23 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-02-28 |
Plexxikon
Berkeley, California, United States Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. The Company has clinical and preclinical stage programs in several therapeutic areas, including metabolic disease, oncology, inflammation, CNS and cardiovascular disease. |
Sell | $805M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-07-05 |
Aegis Lightwave
Woburn, Massachusetts, United States Aegis Lightwave is a privately held company that builds cost-effective solutions for intelligent optical networks. Aegis is the first company to deliver low-cost wavelength-monitoring components and modules that are easily manufactured using proven methods from the semiconductor industry. |
Sell | $52M |
